Publication Name	World Journal of Hepatology
Manuscript ID	9585
Country	France

Received	2014-02-19 09:40
Peer-Review Started	2014-02-19 20:25
First Decision by Editorial Office Director
Return for Revision	2014-04-16 12:08
Revised	2014-04-25 05:41
Publication Fee Transferred
Second Decision by Editor	2014-08-31 16:57
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-08-31 17:13
Articles in Press	2014-08-31 17:13
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-09-30 16:20
Publish the Manuscript Online	2014-10-19 20:39

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Autobiography
Article Title	Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients
Manuscript Source	Unsolicited Manuscript
All Author List	Delphine Bonnet, Matthieu Guivarch, Emilie Bérard, Jean-Marc Combis, Andre Jean Remy, Andre Glibert, Jean-Louis Payen, Sophie Metivier, Karl Barange, Herve Desmorat, Anaïs Palacin, Florence Nicot, Florence Abravanel and Laurent Alric
Funding Agency and Grant Number
Corresponding Author	Laurent Alric, Professor, Internal Medecine, Digestive Department, Pavillon Dieulafoy, CHU Purpan, TSA 40031, Toulouse 31059 cedex, France. alric.l@chu-purpan-toulouse.fr
Key Words	Hepatitis C virus; Hepatitis C; Antiviral therapy; Protease inhibitors; Fibroscan; Liver stiffness; Cirrhosis; Boceprevir; Telaprevir; Ribavirin
Core Tip	To the best of our knowledge, this study marks the first time that a significant link has been shown between a sustained virological response to triple therapy and the liver stiffness measured by elastography at baseline. We also demonstrate that triple therapy is poorly tolerated. Two factors predict the development of serious adverse events: female gender and an initial platelet count of less than 150000/mm3; these factors facilitate the identification of at-risk patients.
Publish Date	2014-10-19 20:39
Citation	Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World J Hepatol 2014; 6(9): 660-669
URL	http://www.wjgnet.com/1948-5182/full/v6/i9/660.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i9.660

Full Article (PDF)	WJH-6-660.pdf
Full Article (Word)	WJH-6-660.doc
Manuscript File	9585-Review.docx
Answering Reviewers	9585-Answering reviewers.pdf
Copyright License Agreement	9585-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	9585-Language certificate.pdf
Peer-review Report	9585-Peer review(s).pdf
Scientific Misconduct Check	9585-CrossCheck.jpg
Scientific Editor Work List	9585-Scientific editor work list.pdf